학술논문
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
Document Type
Academic Journal
Author
Source
Cancer Communications. June, 2023, Vol. 43 Issue 6, p720, 6 p.
Subject
Language
English
Abstract
List of abbreviations Dear Editor, Despite the improved outcome of advanced estrogen receptor‐positive (ER[sup.+]) breast cancer patients treated with endocrine therapy in combination with either a cyclin‐dependent kinase 4/6 inhibitor [...]